

MARKET NEWS

AND

TRENDS

Kurve Technology Announces Agreement With DARA BioSciences; Receives Frost & Sullivan Award

Kurve Technology, Inc., a leader in nasal drug delivery devices, recently announced the signing of an agreement with development-stage pharmaceutical company DARA BioSciences, Inc. (DBI). DBI focuses on the treatment of metabolic diseases, central nervous system disorders, and medical devices.

"We are impressed with the quality and flexibility of Kurve's technology platform and excited about combining Kurve's drug delivery technology platform with DARA's pharmaceutical formulations," said John Didsbury, Executive Vice President of DBI.

"DBI's research and development is the type of leading-edge pharmaceutical science for which our devices were developed," said Marc Giroux, Chairman and CEO of Kurve Technology, Inc. "We are thrilled to be working with the innovative team at DBI."

Incorporating patented Controlled Particle Dispersion and intelligent nasal drug delivery technologies, Kurve's ViaNase electronic atomizer intranasally delivers topical, systemic, and nose-to-brain medical therapies with greater efficacy and efficiency than traditional nasal delivery devices, such as spray pumps. ViaNase is the first nasal drug delivery device that saturates the entire nasal cavity, allowing delivery to the paranasal sinuses. In addition, ViaNase limits peripheral deposition of pharmaceutical formulations into the lungs or stomach. Kurve's most recent device offering (ViaNase ID) incorporates drug pedigree confirmation, lock-out technology, and an electronic display to curb counterfeit drug use and abuse while improving patient compliance.

DARA BioSciences, Inc., incorporated in Delaware in July 2002, is a development-stage company that acquires and develops therapeutic candidates and medical technologies directly or through subsidiaries and is focused on the treatment of metabolic diseases, central nervous system disorders, and cardiovascular indications. DBI is the parent company to Signum Pharmaceuticals, OnsetThera, Inc., NYVARA Pharmaceuticals, Inc., MIKKO Pharmaceuticals, and DARA Therapeutics, Inc. Additionally, DBI holds

positions in Medeikon Corp., Surgi-Vision, Inc., SpineMedica, Inc. and Medivation, Inc.

Kurve also announced that Frost & Sullivan selected it as the recipient of the 2006 Business Development Strategy Leadership of the Year Award in the intranasal drug delivery market for successfully partnering their cutting-edge device technology with pharmaceutical companies.

"The limitations of manual spray pumps have long been known, but few companies have dedicated time and resources to improve delivery technology, instead focusing more on formulation design," says Frost & Sullivan Research Analyst Jason McKinnie. "Kurve has overcome obstacles, such as lack of accuracy, control of droplet size, and regulated velocity, and created a device that maximizes nasal mucosa exposure for both topical, systemic, and nose-to-brain drugs."

"Controlled Particle Dispersion is capable of delivering three preservative-free formulations: dry powder, suspension, and solution, and the individual dose ampoules are capable of storing small molecules, large molecules and proteins," added Mr. McKinnie. "Tests have shown very little degradation to proteins through this delivery, providing the capability to treat diseases or vaccinate with peptides thus boosting its value."

Kurve Technology is ensuring patients will soon get access to a more reliable and effective nasal delivery system and are therefore the worthy recipient of the 2006 Frost & Sullivan Business Development Strategy Leadership of the Year Award for the intranasal drug delivery market. Each year Frost & Sullivan presents this Award to a company that has exhibited excellence in business development within the industry. The Award recognizes the company's ability to best perceive consumer needs, develop products and/or services that meet consumer needs, successfully introduce products or services to the industry, and identify new market segments to expand the existing customer base. Through a combination of vision, technology, and successful marketing, the Award recipient has demonstrated superior market growth skills.